INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma
Clinical trial NCT03692338 · TERMINATED
Trial details
- NCT number
- NCT03692338
- Sponsor
- Duke University
- Status
- TERMINATED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-19
- Primary completion
- 2019-12-09
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.